Date: 2017-07-20
Type of information: Production agreement
Compound: Liproca®Depot
Company: Recipharm (Sweden) LIDDS (Sweden)
Therapeutic area: Cancer - Oncology
Type agreement: production - manufacturing
Action mechanism:
Disease: prostate cancer
Details:
- • On July 20, 2017, Recipharm, the contract development and manufacturing organisation (CDMO), and LIDDS have together set up a manufacturing line for LIDDS’ novel prostate cancer drug, Liproca®Depot, at Recipharm in Solna, Sweden.
The manufacturing line is dedicated to the first product based on LIDDS’ innovative NanoZolid®technology. Clinical trial material has already been produced and the facility is ready for future commercial manufacturing of Liproca® Depot or other pharmaceutical formulations based on the NanoZolid®technology.
- The manufacturing line has been adapted for GMP production and is industrialised according to a unique process invented by LIDDS, involving the installation of novel equipment that is new to the pharmaceutical industry.
Financial terms:
Latest news:
Is general: Yes
